CMMB - Chemomab jumps 35% as NASH candidate meets main goal in Phase 2 trial

• Israeli biotech Chemomab Therapeutics ( NASDAQ: CMMB ) added ~35% pre-market Tuesday after announcing that its candidate for non-alcoholic steatohepatitis (NASH) CM-101 reached the primary endpoint in a Phase 2a trial.
• The 23-patient placebo-controlled trial was designed to evaluate the subcutaneously delivered CM-101 across eight dose levels administered once every two weeks over 16 weeks.
• According to its topline data, the experimental therapy achieved the primary endpoint of safety and tolerability, Chemomab ( CMMB ) said. The CCL24-neutralizing monoclonal antibody was safe and well tolerated leading to only one unrelated serious adverse event, and most of the adverse events were found to be mild.
• CM-101 also achieved reductions in secondary endpoints related to multiple liver fibrosis biomarkers and physiologic assessments conducted at baseline and week 20.
• “We are especially pleased with these encouraging findings given the small size of the study, the short duration of treatment and the relatively low dose of CM-101 that was administered,” Chief Executive of Chemomab ( CMMB ) Dale Pfost remarked.
• In December, Madrigal Pharmaceuticals ( MDGL ), a rival drug developer targeting NASH, surged after releasing late-stage data for its candidate resmetirom.

For further details see: